

Potent anti-hepatoma efficacy of *HCCS1* via dual tumor-targeting gene-virotherapy strategy

JIAN ZHANG^{1,2*}, YU GAN^{1*}, JINFANG GU³, JINGYING HU¹,
XINYUAN LIU³ and XINTAI ZHAO^{1*}

¹Laboratory for Cellular and Molecular Immunology, Shanghai Cancer Institute, Shanghai 200032,

²Department of Medical Oncology, Fudan University Cancer Hospital, Shanghai 200032,

³Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, P.R. China

Received March 26, 2008; Accepted May 14, 2008

DOI: 10.3892/or_00000106

Abstract. We previously demonstrated that hepatocellular carcinoma suppressor 1 (*HCCS1*) exerts potent anti-tumor activity. In this study, we constructed a new dual tumor-targeting oncolytic adenovirus vector, PD55-*HCCS1*, in which E1A was driven by the promoter of progression elevated gene-3, which is hepatoma-specific, and a CMV-*HCCS1* expression cassette replaced E1B55. The PD55-*HCCS1*-mediated selective expression of E1A and *HCCS1* in hepatoma cells and tumor-selective cytotoxicity *in vitro* and *in vivo* demonstrated the strongest inhibition of BEL-7404 cell xenografts in nude mice among a number of control Ad vectors. These data indicated the efficacy and safety of the PD55-*HCCS1* system for HCC treatment.

Introduction

Hepatocellular carcinoma suppressor 1 gene (*HCCS1*) was discovered as a candidate tumor suppressor gene by analysis of the highest-frequency loss of heterozygosity (LOH) region on human chromosome 17p13.3 and positional cloning in hepatocellular carcinoma (HCC) (1,2). *HCCS1* was demonstrated to have a higher frequency of mutations and a significantly lower level of expression in HCC samples than in non-cancerous liver tissues. Additionally, transfection of *HCCS1* into tumor cells markedly reduced the efficiency of

colony formation *in vitro* and inhibited tumor growth *in vivo* (1). These findings suggested that *HCCS1* plays a role in tumor progression and is a novel therapeutic gene for HCC. We have found that a high level of expression of *HCCS1* protein induced apoptosis in hepatoma cells and that the pro-apoptotic process occurred mainly through the mitochondrial and lysosomal pathways (unpublished data).

HCC is one of the most frequently occurring solid cancers and more than half a million people around the world succumb to it each year (3). However, traditional treatments such as surgery, radiotherapy, chemotherapy, and liver transplantation, alone or in various combinations, are not very effective. Therefore, innovative treatments are urgently needed. Cancer gene therapy has been evaluated as a novel and promising treatment modality (4-6). The candidate cancer suppressor gene *HCCS1* may be applied as a potentially therapeutic gene for HCC.

To achieve sufficient anti-tumoral effects, it is critical to deliver therapeutic genes efficiently into target cancer cells (7-9). Adenovirus (Ad) vectors can rapidly infect a broad range of human cells with high efficiency and achieve high levels of transgene expression. Moreover, the Ad viral genome is genetically stable and the inserted foreign genes are generally maintained without change through successive rounds of viral replication (10). These features make Ad vectors attractive in gene therapy. For safety reasons, however, virus vectors employed in conventional cancer gene therapy are generally replication-incompetent viruses, which limit the efficacy of gene transfer by restricting the number of tumor cells to which the therapeutic gene is delivered as well as the transgene copy number per cell. To target this problem, tumor-specific replication-competent viruses have been proposed as vectors (11). We (12) previously constructed an armed therapeutic oncolytic Ad system, ZD55-gene, an E1B55 gene-deleted Ad similar to ONYX-015 (dl1520), but with a cloning site for foreign anti-tumor gene insertion. Such a gene-virotherapy, a marriage of gene therapy and oncolytic virus therapy, is expected to create synergism and deliver therapeutic effects superior to that of each of the single strategies alone, a hypothesis that has been validated in a number of cases (13,14).

Correspondence to: Dr Xintai Zhao, Laboratory for Cellular and Molecular Immunology, Shanghai Cancer Institute, Shanghai 200032, P.R. China
E-mail: xtzhao@online.sh.cn

*Contributed equally

Key words: hepatocellular carcinoma suppressor 1, conditionally replication-competent adenovirus, progression elevated gene-3 promoter, gene therapy, hepatocellular carcinoma

ZD55, the putative p53-dependent vector, is supposed to be attenuated in somatic cells because of the deletion of E1B55, but actually its replication appears to be similar to ONYX-015 which depends not only on p53 status but also on individual cell line characteristics concerning cell cycle regulation, induction of apoptosis, and the applied MOI (15). To minimize the toxicity of replication-competent viral vectors, a strategy using tumor-selective promoter(s) to control the expression of early viral gene(s) essential for replication, such as E1A, has been used (16,17). Progression elevated gene-3 (PEG-3) is a rodent gene identified by subtraction hybridization and it displays elevated expression following transformation by diversely acting oncogenes, DNA damage, and cancer cell progression. The promoter of PEG-3 (PEG-3p) displays robust activity in a broad spectrum of human cancer cell lines but has marginal activity in corresponding normal cells (18). The mechanism underlying this cancer specificity involves defined binding with specific promoter sequences by PEG-3, activator protein-1 (AP-1), and polyoma enhancer activator protein-3 (PEA-3), which are expressed at elevated levels in the majority of cancer cells (19). Recombinant Ads in which E1A expression was controlled by PEG-3p resulted in selective replication in rodent and human cancer cells (18). However, no evidence exists that PEG-3p showed a higher transcriptional activity in malignant versus normal liver cells.

To evoke a potent and selective destruction of HCC with minimal injury of normal cells, we initially observed the higher transcriptional activity of PEG-3p in hepatoma cells, and based on the ZD55-gene system, we constructed a dual tumor-targeting recombinant Ad whose E1A was driven by PEG-3p, and E1B55 was replaced with a *HCCS1* expressing cassette. The anti-tumoral efficacy of this dual tumor-targeting gene-virotherapy system Ad PD55-HCCS1 was evaluated for HCC *in vitro* and *in vivo*.

Materials and methods

Cell lines and culture conditions. The normal human liver cell line L-02 (WT p53), and human hepatoma cell lines BEL-7404 (mutated p53), BEL-7405 (mutated p53) and QGY-7703 (low p53 expression) were purchased from Shanghai Cell Collection (P.R. China). The human embryo kidney cell line HEK293 was obtained from Microbix Biosystems, Inc. (Toronto, Ontario, Canada). The L-02, BEL-7405, QGY-7703 and HEK293 cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Hyclone, Logan, UT) supplemented with 10% fetal bovine serum (FBS) and the BEL-7404 cell line was grown in RPMI-1640 supplemented with 10% FBS at 37°C in 5% CO₂.

Control Ads. Ad.Null, Ad-CMV-HCCS1 and Ad-PEG-3p-HCCS1 are replication-incompetent Ads. ONYX-015 and ZD55-HCCS1 are conditionally replication-competent Ads, in which ONYX-015 is structurally and functionally similar to ZD55.Null. The summary of the genetic features of the Ads used in this study are shown in Table I.

Plasmid construction. The regions of E1A promoter (342-552) of pZD55 was deleted by overlap extension PCR. Briefly, by using the pZD55 DNA as a template, the region containing




Figure 1. (a) Transcriptional activity of PEG-3p in normal and malignant liver cells. The indicated cells were transfected with pGL3-PEG-3p and luciferase activity was measured at 48 h post-transfection. The luciferase activity was normalized by β -galactosidase activity. The data represent the mean \pm SD of three independent experiments, each performed in triplicate. (b) Schematic structures of Ad(WT), ZD55-HCCS1 and PD55-HCCS1. In PD55-HCCS1, the normal E1A promoter (342-552 bp) was replaced by PEG-3p, and the *HCCS1* expression cassette replaced E1B55.

nucleotides 22-342 was amplified with the primers: 1F 5'-TCCTGTGGATCCGGGCCCCCATTTTC-3' and 1R 5'-CAGTGATCAGCGGCCGACGCGTATATTACGCGCTATGAGTAACAC-3'; and the region containing nucleotides 552-1359 was amplified with the primers: 2F 5'-TATACGCGTGCGGCCGCTGATCATGAAATGAGACATATTATC-3' and 2R 5'-TACTACTATTGCATTCTCTAGACACA-3'. PCR products contained a 26-bp sequence (underlined) at the end of the deleted region, which were complementary to each other. This 26-bp sequence comprises of the restriction enzyme sites of *Mlu*I, *Not*I and *Bcl*I. A fragment of ~1100 bp was amplified with the primers 1F and 2R by using the two PCR products as the template. Finally, the ~1100 bp PCR product was supplanted into pZD55 with *Bam*HI/*Xba*I digestions on the insert and vector to construct the plasmid pMD55.

The minimally active region of PEG-3 promoter was obtained from rat genomic DNA by PCR and cloned into a pGL3-basic vector (Promega, Madison, MI) to generate the luciferase reporter plasmid pGL3-PEG-3p. Then the PEG-3p was cloned into pMD55 to yield plasmid pPD55. The *HCCS1* cDNA was cloned into pCA13 (Microbix Biosystems) to yield pCA13-HCCS1. From this plasmid, the whole *HCCS1* gene expression cassette was excised with *Bgl*III and inserted into pPD55 to produce pPD55-HCCS1. The constructed plasmids were confirmed by restrictive endonuclease digestions, PCR and DNA sequencing.

Luciferase assay. Cells were plated at a density of 1.0×10^5 cells/ml and transfected with pGL3-PEG-3p using Lipo-

 **SPANDIDOS** summary of the genetic features of the Ads used in this study.
PUBLICATIONS

	E1A	Promoter of E1A	E1B55	Foreign gene	Promoter of foreign gene
Ad(WT)	+	WT E1Ap	+	-	
Ad.Null	-		-	-	
ONYX-015	+	WT E1Ap	-	-	
Ad-CMV-HCCS1	-		-	+	CMVp
Ad-PEG-3p-HCCS1	-		-	+	PEG-3p
ZD55-HCCS1	+	WT E1Ap	-	+	CMVp
PD55-HCCS1	+	PEG-3p	-	+	CMVp

fectamine 2000 (Gibco-BRL, Gaithersburg, MD) 24 h later. Co-transfection of the β -galactosidase expression plasmid was performed to normalize for transfection efficiency. At 48 h post-transfection, cells were washed twice with phosphate-buffered saline (PBS) and lysed in the reporter lysis buffer (Promega). The luciferase and β -galactosidase activity were then quantified.

Packaging and verification of recombinant Ad. The dual tumor-targeting recombinant Ad, PD55-HCCS1, was constructed by standard homologous recombination techniques using plasmid pPD55-HCCS1 and the Ad packaging plasmid pBHGE3 (Microbix Biosystems) in HEK293 cells. The recombinant Ad was isolated from a single plaque, expanded in HEK293 cells and purified by cesium chloride gradient ultracentrifugation. Titers were determined by plaque assay on HEK293 cells. The virus was identified by PCR using the primers ZD-sense 5'-AGAGCCCATGGAACCCGAGA-3' and ZD-antisense 5'-CATCGTACCTCAGCACCTTCCA-3' which are complementary to the flank region sequences of E1B55.

Western blot analyses of E1A and HCCS1. Cells were infected with Ads at a multiplicity of infection (MOI) of 10 for 48 h. The cells were harvested, lysed and centrifuged, and the supernatants were used as total cell lysates for Western blot analyses. The anti-E1A mouse monoclonal antibody (M58; NeoMarkers, Fremont, CA) and anti-HCCS1 mouse monoclonal antibody (prepared by our laboratory) were used to detect the corresponding proteins.

Crystal violet staining assay for evaluating cytolysis in vitro. Cells were plated in 24-well plates (2×10^4 cells/well) 24 h before infection. Infection was performed with each virus in 500 μ l serum-free growth medium at the indicated MOI (0.01, 0.1, 1 and 10) and incubation was carried out for 2 h at 37°C under 5% CO₂. The infection medium was replaced with medium containing 5% FBS. Seven days after infection, cells were fixed with formalin solution and stained with crystal violet. Twenty minutes later, the plates were washed with water to remove excess dye and then dried. Images of the plates were captured with a scanner.

Colorimetric cell viability assay in vitro. A colorimetric assay via 3-(4,5-dimethylthiazol)-2,5-diphenyltetrazolium bromide (MTT, Roche Molecular Biochemicals, Indianapolis, IN) was

used to assess cell viability after viral infection. Cells were plated at 4×10^3 /well in 96-well plates. After incubation for 24 h, the cells were infected with 10 MOI of the viruses. Ten microliters of MTT (10 mg/ml) were added to each well at different time points (24, 48, 72 and 96 h) and the cells were incubated at 37°C for 4 h. The supernatant was discarded and dimethyl sulfoxide (DMSO), as the solubilizing solution, was added at 150 μ l/well. Plates were read at 492 nm with an ELISA reader (Bio-Tek Instruments, Winooski, VT). Cell viability was calculated as:

$$\text{Cell viability} = \frac{A_{492\text{nm}} \text{ mean value of infected cells}}{A_{492\text{nm}} \text{ mean value of uninfected cells}} \times 100\%$$

Anti-tumor activity in vivo. BALB/c athymic nude mice at 4-5 weeks old were obtained from the Shanghai Cancer Institute (P.R. China). Mice were inoculated subcutaneously with BEL-7404 cells (2×10^6). After 14 days, when the tumor volume reached 100 mm³ in size, the mice were randomly divided into three groups (n=7 per group) for PD55-HCCS1, ZD55-HCCS1 and PBS, respectively. The viruses (5×10^8 PFU) or PBS were injected intratumorally once every other day for 4 times. Since the beginning of tumor cell inoculation, tumor size was measured by a Vernier caliper every 7 days. The tumor volume (mm³) was calculated as (length x width²)/2. The mice were sacrificed 35 days after inoculation, and tumors were excised and weighed.

Immunohistochemical assay. Tumor tissues from the above-treated mice were fixed in 4% paraformaldehyde, processed in paraffin, sectioned with 4 μ m thickness, and then dewaxed, hydrated and incubated in methanol-H₂O₂ for 20 min to remove endogenous peroxidase. Tissue sections were stained with the HCCS1 mouse monoclonal antibody (prepared by our laboratory) according to the immunohistochemical staining procedures provided by the EnvisionTM detection kit (Dako, Glostrup, Denmark).

Results

PEG-3p showed higher transcriptional activity in malignant versus normal liver cells. As shown in Fig. 1a, the relative luciferase activity in QGY-7703, BEL-7404 and BEL-7405 cells was 1.5-, 3.9-, and 4.7-fold of that in L-02 cells,




Figure 2. PD55-HCCS1 demonstrates tumor-specific transgene expression and toxicity *in vivo*. (a) Western blot analyses of E1A and *HCCS1* expression in different liver cell lines. The L-02, BEL-7404 and QGY-7703 cells were uninfected (control) or infected with the indicated Ad at a MOI of 10 for 48 h. After cells were harvested, lysed and centrifuged, the supernatants were used as total cell lysates for Western blot analyses of E1A and *HCCS1*. At each bottom panel, β-actin expression serves as a loading control. (b) Crystal violet staining assay *in vitro*. Cells were infected with the indicated viruses at different MOIs as labeled. Seven days later, cells were stained with crystal violet. Similar results were obtained in three independent experiments. (c) Cytotoxic activity of PD55-HCCS1 *in vitro*. Cytotoxic effects in L-02, BEL-7404 and QGY-7703 cells were analyzed via MTT assay at different time points (24, 48, 72 and 96 h) after infection with PD55-HCCS1 or Ad.Null, ONYX-015, Ad-CMV-HCCS1, Ad-PEG-3p-HCCS1, ZD55-HCCS1 at 10 MOI; **P*<0.05 and ***P*<0.01.

respectively. The data indicated that the PEG-3p was able to drive the expression of exogenous genes preferentially in hepatoma cells.

Verification of PD55-HCCS1 construction. For safety purposes, we produced a replication-competent tumor-targeting Ad named PD55-HCCS1 by replacing the normal E1A regulatory elements with PEG-3p and inserting the *HCCS1* expression cassette in the E1B55 region (Fig. 1b). A correct fragment of 3042 bp was obtained in PCR using primers ZD-sense and -antisense, which was different from the fragments of 1153 and 254 bp, respectively, for WT Ad5 and PD55.Null. In addition, a 350 bp PCR product was amplified with PEG-3p primers in PD55-HCCS1 (data not shown).

PD55-HCCS1 mediates cancer cell-specific E1A and *HCCS1* expression. BEL-7404 (mutated p53), QGY-7703 (low p53 expression) and L-02 (WT p53) cells were infected with Ad.Null, ONYX-015, Ad-CMV-HCCS1, Ad-PEG-3p-HCCS1, ZD55-HCCS1, and PD55-HCCS1, respectively, and the expression of E1A and *HCCS1* protein in cells was assessed by Western blotting. In BEL-7404 and QGY-7703, infection with the three replication-competent Ads (ONYX-015, ZD55-HCCS1, and PD55-HCCS1) produced abundant E1A proteins, which indicates viral replication. In contrast, L-02 infected with ONYX-015 or ZD55-HCCS1, but not PD55-HCCS1, resulted in a robust expression of E1A proteins (Fig. 2a). No E1A proteins were detected in any cells infected

with replication-incompetent Ads (Ad.Null, Ad-CMV-HCCS1 and Ad-PEG-3p-HCCS1).

HCCS1 protein expression resulting from Ad infection differed for the four transgenes containing Ads. In L-02 cells, infection with ZD55-HCCS1 and Ad-CMV-HCCS1 resulted in a robust *HCCS1* production, whereas infection with Ad-PEG-3p-HCCS1 or PD55-HCCS1 resulted in barely detectable (Ad-PEG-3p-HCCS1) or very low (PD55-HCCS1) levels of *HCCS1* production (Fig. 2a). In hepatoma cell lines, infection with Ad-CMV-HCCS1, Ad-PEG-3p-HCCS1, ZD55-HCCS1, or PD55-HCCS1 produced a significant *HCCS1* expression and the two replication-competent vectors resulted in higher *HCCS1* expression levels than the former two replication-incompetent vectors (Fig. 2a). Taken together, these findings documented that PEG-3p facilitated hepatoma cell-selective Ad replication and *HCCS1* expression.

Selective anti-tumor activity and safety of PD55-HCCS1 for HCC in vitro. The cytopathic effects (CPE) of PD55-HCCS1 on BEL-7404, QGY-7703 and L-02 were investigated with crystal violet staining assay. Compared to Ad.Null, ONYX-015, Ad-CMV-HCCS1, Ad-PEG-3p-HCCS1 and ZD55-HCCS1, PD55-HCCS1 showed an approximate cytotoxicity in the L-02 cells. However, PD55-HCCS1 infection resulted in an ~10-100-fold higher anti-tumor activity than ONYX-015, Ad-CMV-HCCS1 or Ad-PEG-3p-HCCS1 infection, and an ~1-10-fold higher anti-tumor activity than ZD55-HCCS1 infection (Fig. 2b).




Figure 3. Antitumoral efficacy of PD55-HCCS1 *in vivo*. (a) BALB/c nude mice were inoculated subcutaneously with BEL-7404 cells (2×10^6). When tumors reached 100 mm³, the mice were divided into three groups and injected intratumorally with PBS, ZD55-HCCS1 or PD55-HCCS1 once every other day for four times. Tumor volume was recorded. Data are expressed as means of tumor volume over time (mean \pm SD, n = 7). The arrow indicates the start of adenovirus injection; * $P < 0.05$ and ** $P < 0.01$. (b) The tumors were excised after the mice were sacrificed 35 days after inoculation. (c) The tumors from (b) were weighed and data were expressed as a histogram to reflect the means of tumor weight after different treatments; * $P < 0.05$ and ** $P < 0.01$. (d) H&E and immunohistochemical staining of HCCS1 protein in the xenografts of PBS-, ZD55-HCCS1- and PD55-HCCS1-treated animals. The black arrows indicate the expression of HCCS1. The red arrows point to the necrotic tissues (magnification, x400).

The selective inhibition of liver cancer cells by PD55-HCCS1 was further corroborated by MTT colorimetric assay (Fig. 2c). PD55-HCCS1 showed a similar cytotoxicity in L-02 cells as Ad-CMV-HCCS1 ($P > 0.05$), a significantly less cytotoxicity than ZD55-HCCS1 ($P < 0.01$), and a higher cytotoxicity than Ad.Null, ONYX-015 or Ad-PEG-3p-HCCS1 ($P < 0.01$). In contrast, PD55-HCCS1, at 96 h after viral infection, demonstrated more cytotoxicity in BEL-7404 or QGY-7703 cells than any of the five control Ads ($P < 0.05$).

Antitumoral efficacy of PD55-HCCS1 in nude mice. Since PD55-HCCS1 had demonstrated dual tumor-targeting characteristics *in vitro* which suggested its higher safety profile for treating hepatoma, experiments were performed on nude mice to identify whether PD55-HCCS1 was able to specifically inhibit tumor growth *in vivo*. In our previous experiments (data not shown), ZD55-HCCS1 has been confirmed to be the most effective therapeutic Ad *in vivo* (and *in vitro*) against SW-620 and BEL-7404, among all types of Ads mentioned above (not including the new recombinant PD55-HCCS1). Therefore, ZD55-HCCS1 may be used as a good positive control in the PD55-HCCS1 experiment *in vivo*.

As shown in Fig. 3a, a significant inhibition of tumor growth was observed in the mice treated with PD55-HCCS1 or ZD55-HCCS1 compared with those treated with PBS ($P < 0.01$). The suppression efficacy of PD55-HCCS1 on tumor growth was also found to be greater than that of ZD55-HCCS1 ($P < 0.05$). The mice were sacrificed 35 days after inoculation. As shown in Fig. 3b and c, the mean wet weight of tumors

that received injection of PD55-HCCS1 was less than those receiving an injection of ZD55-HCCS1 ($P < 0.05$) or PBS ($P < 0.01$). The inhibition rate of the tumor weight from PD55-HCCS1 reached $(77.41 \pm 11.65)\%$.

Expression of HCCS1 was demonstrated by immunohistochemical staining in BEL-7404 cells in mice treated with ZD55-HCCS1 or PD55-HCCS1 which presented as concentrated positive staining of cytoplasm (Fig. 3d). The expression level of HCCS1 in cells treated with PD55-HCCS1 was comparable to or even higher than those treated with ZD55-HCCS1. The results indicated an effective expression of HCCS1 protein from the two recombinant Ad infections in xenograft *in vivo*.

Discussion

HCCS1 has been identified as a novel candidate for tumor suppressor genes in our previous study (1). After transfection in human hepatocarcinoma cells, HCCS1 exhibited significant inhibition of cell proliferation *in vitro* and *ex vivo*. To confirm the anti-tumor efficacy of the HCCS1 gene, we have demonstrated in our recent study as well as this study that the HCCS1 gene, delivered by Ad-CMV-HCCS1 and ZD55-HCCS1, which were replication-incompetent and -competent Ads, respectively, and where HCCS1 expression was driven by the CMV promoter, provided sufficient inhibition of tumor cell growth *in vitro* (Fig. 2b and c) and *in vivo* (data not shown). These data further established the potent activity of HCCS1 in cancer gene therapy. In order to enhance the safety of cancer

gene therapy by utilizing *HCCS1* as the therapeutic gene, Ad-PEG-3p-*HCCS1* was produced where *HCCS1* was driven by PEG-3p, a tumor-selective promoter, and this vector showed less cytotoxicity than Ad-CMV-*HCCS1* in L-02 cells (Fig. 2c). Based on the above findings and in order to enhance the tumor-selective and therapeutic effect, PD55-*HCCS1*, which was a recombinant conditionally replication-competent Ad, was generated. Its E1A was driven by PEG-3p and the CMV-*HCCS1* expression cassette was inserted in the region of the deleted E1B55. Since PD55-*HCCS1* replicated better in cancer versus normal cells and preferentially expressed *HCCS1* protein in tumor cells, it demonstrated a strong selectively inhibitory activity in a number of HCC cell lines tested and the selective inhibition was superior to ONYX-015, Ad-CMV-*HCCS1*, Ad-PEG-3p-*HCCS1* and ZD55-*HCCS1*. The *in vivo* experiment showed that PD55-*HCCS1* produced a marked tumor growth suppression greater than that of ZD55-*HCCS1*, which may be explained by the result of immunohistochemical staining, in that the expression level of *HCCS1* in cells treated with PD55-*HCCS1* was comparable to or even higher than those treated with ZD55-*HCCS1*.

The cytotoxicity of Ad-CMV-*HCCS1* was similar to Ad.Null in L-02 (Fig. 2b and c) but Ad-CMV-*HCCS1* had a higher cytotoxicity than Ad.Null in HCC cells. It suggested that *HCCS1* as a novel tumor suppressor gene candidate alone has tumor-selective cytotoxicity to some extent. The precise mechanism is still unclear and more studies on normal cell lines from different origins are needed to verify whether it is an extensive phenomenon. We find that PEG-3p has a higher transcriptional activity in malignant versus normal liver cells by luciferase assay. Since early activation of AP-1 probably contributes to the acquisition of a transformed phenotype during hepatocarcinogenesis (20), it is possible that the up-regulation or activation of AP-1 plays a role in robust PEG-3p transcriptional activity in HCC cells.

Most tumor suppressor genes efficiently trigger apoptosis in human cancer cells via death receptors or the mitochondrial pathway. In contrast, conditionally replication-competent Ad can kill a variety of human cancer cells via a process morphologically distinct from apoptosis which is characterized by chromosome condensation and nuclear shrinkage and fragmentation (21). These two types of anticancer elements using different cytotoxic machineries have been shown to induce a synergistic effect (12,13). Therefore, *HCCS1* as a tumor suppressor gene is suitable for use in combination with replication-competent Ad to establish a novel compound cancer therapeutic approach.

In summary, this study has established the anti-tumor activity of *HCCS1*, a tumor suppressor gene candidate, *in vitro* and *in vivo*. This novel dual tumor-targeting Ad PD55-*HCCS1* gene-virotherapy system is capable of selective replication in lysis of, and efficient expression of *HCCS1* protein in malignant liver cells, and is a potentially effective and safe therapeutic approach for HCC.

Acknowledgements

This study was supported by the grants from the Key Programs of the National Natural Science Foundation of P.R. China (No. 30330350).

References

1. Zhao XT, Li JJ, He Y, *et al*: A novel growth suppressor gene on chromosome 17p13.3 with a high frequency of mutation in human hepatocellular carcinoma. *Cancer Res* 61: 7383-7387, 2001.
2. Zhao XT, He M, Wan DF, *et al*: The minimum LOH region defined on chromosome 17p13.3 in human hepatocellular carcinoma with gene content analysis. *Cancer Lett* 190: 221-232, 2003.
3. Bosch FX, Ribes J, Cléries R, *et al*: Epidemiology of hepatocellular carcinoma. *Clin Liver Dis* 9: 191-211, 2005.
4. Ruiz J, Qian C, Drozdik M, *et al*: Gene therapy of viral hepatitis and hepatocellular carcinoma. *J Viral Hepat* 6: 17-34, 1999.
5. Mitry RR, Mansour MR, Havlik R, *et al*: Gene therapy for liver tumours. *Adv Exp Med Biol* 465: 193-205, 2000.
6. Qian C, Drozdik M, Caselmann WH, *et al*: The potential of gene therapy in the treatment of hepatocellular carcinoma. *J Hepatol* 32: 344-351, 2000.
7. Roth JA and Cristiano RJ: Gene therapy for cancer: What have we done and where are we going? *J Natl Cancer Inst* 89: 21-39, 1997.
8. Gomez-Navarro J, Curiel DT and Douglas JT: Gene therapy for cancer. *Eur J Cancer* 35: 2040-2053, 1999.
9. Vile RG, Russel SJ and Lemoine NR: Cancer gene therapy: hard lessons and new courses. *Gene Ther* 7: 2-8, 2000.
10. Robbins PD and Ghivizzani SC: Viral vectors for gene therapy. *Pharmacol Ther* 1: 35-47, 1998.
11. Bauerschmitz GJ, Barker SD and Hemminki A: Adenoviral gene therapy for cancer: From vectors to targeted and replication-competent agents. *Int J Oncol* 6: 1161-1174, 2002.
12. Zhang ZL, Zou WG, Luo CX, *et al*: An armed oncolytic adenovirus system, ZD55-gene, demonstrating potent antitumoral efficacy. *Cell Res* 13: 481-489, 2003.
13. Zhao LL, Gu JF, Dong AW, *et al*: Potent antitumor activity of oncolytic adenovirus expressing mda-7/IL-24 for colorectal cancer. *Hum Gene Ther* 16: 845-858, 2005.
14. Zhang YH, Gu JF, Zhao LL, *et al*: Complete elimination of colorectal tumor xenograft by combined manganese superoxide dismutase with tumor necrosis factor-related apoptosis-inducing ligand gene virotherapy. *Cancer Res* 66: 4291-4298, 2006.
15. Rothmann T, Hengstermann A, Whitaker NJ, *et al*: Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. *J Virol* 72: 9470-9478, 1998.
16. Ohashi M, Kanai F, Tateishi K, *et al*: Target gene therapy for alpha-fetoprotein-producing hepatocellular carcinoma by E1B55k-attenuated adenovirus. *Biochem Biophys Res Commun* 282: 529-535, 2001.
17. Takahashi M, Sato T, Sagawa T, *et al*: E1B-55K-deleted adenovirus expressing E1A-13S by AFP-enhancer/promoter is capable of highly specific replication in AFP-producing hepatocellular carcinoma and eradication of established tumor. *Mol Ther* 5: 627-634, 2002.
18. Su ZZ, Sarkar D, Emdad L, *et al*: Targeting gene expression selectively in cancer cells by using the progression-elevated gene-3 promoter. *Proc Natl Acad Sci USA* 102: 1059-1064, 2005.
19. Su ZZ, Shi Y and Fisher PB: Cooperation between AP1 and PEA3 sites within the progression elevated gene-3 (PEG-3) promoter regulate basal and differential expression of PEG-3 during progression of the oncogenic phenotype in transformed rat embryo cells. *Oncogene* 19: 3411-3421, 2000.
20. Liu P, Kimmoun E, Legrand A, *et al*: Activation of NF-kappaB, AP-1 and STAT transcription factors is a frequent and early event in human hepatocellular carcinomas. *J Hepatol* 37: 63-71, 2002.
21. Abou EI, Hassan MA, Meulen-Muileman van der I, *et al*: Conditionally replicating adenoviruses kill tumor cells via a basic apoptotic machinery-independent mechanism that resembles necrosis-like programmed cell death. *J Virol* 78: 12243-12251, 2004.